SCHEMBL20130168

SCHEMBL20130168

Cc1ccc(-c2cnc3c(c2)n(CC(=O)N2CCC2)c(=O)n3CCF)s1

nearest known ligand 0.82

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 20/20 0.82
GRIN1 Q05586 18/20 0.82
CYP2D6 P10635 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20130167 0.93 GRIN2B (0.80) GRIN2BGRIN1CYP2D6
SCHEMBL20130220 0.91 GRIN2B (0.78) GRIN2BGRIN1CYP2D6
SCHEMBL29635424 0.90 GRIN1 (1.00) GRIN2BGRIN1CYP2D6
SCHEMBL20129967 0.90 GRIN1 (1.00) GRIN2BGRIN1CYP2D6
SCHEMBL20130068 0.88 GRIN1 (0.96) GRIN2BGRIN1CYP2D6
SCHEMBL29635417 0.88 GRIN1 (1.00) GRIN2BGRIN1CYP2D6
SCHEMBL20134279 0.88 GRIN1 (1.00) GRIN2BGRIN1CYP2D6
SCHEMBL29635496 0.83 GRIN1 (1.00) GRIN2BGRIN1CYP2D6
SCHEMBL20130004 0.83 GRIN1 (1.00) GRIN2BGRIN1CYP2D6
SCHEMBL20130219 0.82 GRIN2B (0.79) GRIN2BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338341-A1 SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 US disclosed
US-11759455-B2 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2023-09-19 US disclosed
US-20180125826-A1 SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (JP) 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11759455-B2 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators GRIN2B, GRIN2A, GRIN2C GRIN2B 1/4885GRIN1 6/4885CYP2D6 1133/4885
US-20180125826-A1 SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN2C GRIN2B 1/4885GRIN1 6/4885CYP2D6 1133/4885
US-20230338341-A1 SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN2C GRIN2B 1/4885GRIN1 6/4885CYP2D6 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.